Key facts
- TomoWave’s last known valuation is $25.0M (Feb 2025).
- It has raised $18.4M; the latest was Later Stage VC ($10.0M) in Feb 2025.
- Notable investors include National Institutes of Health, Horizon 2020, National Cancer Institute.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for TomoWave
- ·The full record, as it builds
Funding rounds
No funding rounds for TomoWave are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TomoWave
Developer of proprietary quantitative optoacoustic tomography systems designed to aid doctors in detecting cancer and image-guided interventions. The company's systems provide doctors with the capability for 3D visualization through the human body, like they would see with their own eyes, and understand organ functions by providing molecular distributions within anatomical tissue structures, enabling doctors and healthcare organizations to provide image guidance for therapeutic and surgical interventions.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2010
- Employees
- 28
- Website
- tomowave.com/
- Ownership
- Privately Held (backing)
TomoWave doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TomoWave shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TomoWave in its N-PORT filings yet. We sweep new filings monthly.